Trial Profile
MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Meloxicam/rizatriptan (Primary) ; Meloxicam; Rizatriptan
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Acronyms MOMENTUM
- Sponsors Axsome Therapeutics
- 15 Apr 2024 According to an Axsome Therapeutics media release, the company will present data from MOMENTUM and INTERCEPT Phase 3 trials at the American Academy of Neurology (AAN) 2024 annual meeting, being held April 13-18, 2024, in Denver, Colorado.
- 07 Aug 2023 According to an Axsome Therapeutics media release, Company now anticipates resubmission of the NDA in the first half of 2024.
- 27 Apr 2023 Results of pooled analysis from two studies(MOMENTUM: N=1594 and INTERCEPT : N=352) assessing efficacy of AXS-07 compared to placebo in patients with risk factors for inadequate treatment response to acute migraine medication presented at the 75th Annual Meeting of the American Academy of Neurology 2023